Education
About Us
Working with TipRanks
Follow Us
VolitionRX Ltd. (VNRX)
:VNRX
VNRX Stock Chart & Stats
$0.45
$0.01(1.52%)
At close: 4:00 PM EST
$0.45
$0.01(1.52%)
Day’s Range― - ―
52-Week Range$0.27 - $0.94
Previous CloseN/A
Volume29.92K
Average Volume (3M)995.63K
Market Cap
$38.24M
Enterprise Value$83.20M
Total Cash (Recent Filing)$199.41K
Total Debt (Recent Filing)$11.26M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Mar 31, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding122,801,575
10 Day Avg. Volume825,693
30 Day Avg. Volume995,625
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-2.08
Price to Sales (P/S)42.09
P/FCF Ratio-1.96
Enterprise Value/Market Cap2.18
Enterprise Value/Revenue56.52
Enterprise Value/Gross Profit56.52
Enterprise Value/Ebitda-4.11
Forecast
1Y Price Target
$2.50Price Target Upside455.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Licensing AgreementsVolitionRx has entered a research license and exclusive commercial option rights agreement with Werfen, a global leader in in vitro diagnostics, which aligns with their strategy to out-license proprietary tests.
Market ExpansionThe co-marketing agreement with Hologic is anticipated to expand the customer base for Volition’s services.
Revenue GrowthRevenue grew 32%, and more licensing deals are expected, potentially boosting Volition's topline growth.
Bears Say
Financial UncertaintyConcerns exist regarding Volition's balance sheet, with a low cash position and high burn rate indicating a need for additional capital.
Partnership Strategy RisksThere is high uncertainty about partnership strategies, particularly regarding timing and deal structure.
Revenue Performance3Q25 revenue of $0.63M was slightly lower than the consensus of $0.72M.
VolitionRX News
VNRX FAQ
What was VolitionRX Ltd.’s price range in the past 12 months?
VolitionRX Ltd. lowest stock price was $0.27 and its highest was $0.94 in the past 12 months.
What is VolitionRX Ltd.’s market cap?
VolitionRX Ltd.’s market cap is $38.24M.
When is VolitionRX Ltd.’s upcoming earnings report date?
VolitionRX Ltd.’s upcoming earnings report date is Mar 31, 2026 which is in 112 days.
How were VolitionRX Ltd.’s earnings last quarter?
VolitionRX Ltd. released its earnings results on Nov 13, 2025. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.044 by -$0.006.
Is VolitionRX Ltd. overvalued?
According to Wall Street analysts VolitionRX Ltd.’s price is currently Undervalued.
Does VolitionRX Ltd. pay dividends?
VolitionRX Ltd. does not currently pay dividends.
What is VolitionRX Ltd.’s EPS estimate?
VolitionRX Ltd.’s EPS estimate is -0.05.
How many shares outstanding does VolitionRX Ltd. have?
VolitionRX Ltd. has 122,801,575 shares outstanding.
What happened to VolitionRX Ltd.’s price movement after its last earnings report?
VolitionRX Ltd. reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.044. Following the earnings report the stock price went down -5.714%.
Which hedge fund is a major shareholder of VolitionRX Ltd.?
Currently, no hedge funds are holding shares in VNRX
VolitionRX Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (455.56% Upside)
$2.50 (455.56% Upside)
Blogger Sentiment
Bullish
VNRX Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $239.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 10.6%
Last 30 Days ▲ 10.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-49.14%
Trailing 12-Months
Company Description
VolitionRX Ltd.
VolitionRX (VNRX) is a biotechnology company focused on developing and commercializing innovative blood-based diagnostic tests for various cancers. The company operates primarily in the healthcare sector, leveraging its proprietary Nucleosomics technology to detect cancer through the analysis of nucleosomes—DNA fragments released by dying cells. VolitionRX aims to improve early cancer detection, thereby increasing treatment success rates and potentially saving lives with its core products designed for clinical use.
VNRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in revenue growth, cost management, and strategic partnerships with major companies like Werfen and Hologic. Scientific advancements also promise future potential. However, challenges remain, such as unpredictable revenue and uncertainty in closing additional licensing agreements.View all VNRX earnings summariesVNRX Stock 12 Month Forecast
Average Price Target
$2.50
▲(455.56% Upside)
Technical Analysis
Ownership Overview
10.71% Insiders
1.92% Mutual Funds
10.72% Other Institutional Investors
75.80% Public Companies and
Individual Investors